Peptides for Immune & Anti-inflammatory

This research area has a distinctive split: 22 approved compounds and 12 research-only compounds, with nothing in between. There are zero investigational peptides currently in clinical trials for immune or anti-inflammatory indications — a gap that reflects either the maturity of the approved compounds or the difficulty of advancing new immune-modulating peptides through regulatory pathways.

The approved side includes some of the oldest peptide drugs in clinical use. Vancomycin, bacitracin, and colistin are antimicrobial peptides that have been in service for decades. Cyclosporine — technically a cyclic peptide — is a cornerstone of transplant medicine. Newer approvals like zilucoplan (complement inhibitor for myasthenia gravis) and motixafortide (stem cell mobilisation) show the category is still producing novel mechanisms.

The research tier is dominated by thymic peptides — thymosin alpha-1, thymosin beta-4, thymalin, thymulin — and other immune modulators like KPV, LL-37, and VIP. These compounds are widely discussed in biohacking and grey-market communities, but their clinical evidence remains limited to preclinical models and small uncontrolled studies. BPC-157 and TB-500 also appear here due to their documented anti-inflammatory properties, though they are primarily categorised under tissue repair.